For patients with obesity, blood tests help assess glucose metabolism, liver function, lipid profiles, thyroid hormones, and inflammatory markers—parameters that influence the choice of pharmacological therapy. Based on clinical guidelines and Body Mass Index (BMI), physicians may prescribe weight-management medications such as semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), tirzepatide (Mounjaro), naltrexone/bupropion (Mysimba), phentermine/topiramate (Qsymia), or orlistat (Xenical). Ongoing laboratory follow-up ensures correct dosage adjustments, minimizes side effects, and tracks metabolic response.
Similarly, in the treatment of erectile dysfunction, hormone panels—including testosterone, prolactin, and thyroid levels—help identify underlying causes and guide the use of medications. Treatment options include sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), avanafil (Spedra), alprostadil, and, in some cases, testosterone replacement therapy. Laboratory assessments are crucial not only to confirm the medical necessity of such treatments but also to rule out contraindications and monitor cardiovascular safety.
In countries like Finland, laboratory results can be integrated into digital healthcare platforms, enabling remote consultations, electronic prescriptions, and secure national health recordkeeping. This model supports efficient, evidence-based care delivery—linking laboratory insights directly to personalized therapeutic decisions.